Treatment of the Choroidal Neovascular Membrane by Ranibizumab (Lucentis): A Case Report
Authors:
P. Němec; Ž. Benešová; L. Hejsek
Authors place of work:
Oční klinika 1. LF UK a ÚVN, Praha, přednosta doc. MUDr. Jiří Pašta, CSc.
Published in the journal:
Čes. a slov. Oftal., 66, 2010, No. 3, p. 134-137
Category:
Case Report
Summary
A 73-year-old woman presented with a best-corrected visual acuity of 6/9 in her right eye and 6/36 in her left eye. Fundus examination revealed signs of age related macular degeneration in both eyes. In her right eye it was just dry form of the disease, in left one an elevated lesion associated with retinal cystoid edema was detected. Ocular coherence tomography and fluorescein angiogram confirmed a subfoveal occult choroidal neovascular membrane. We decided for intravitreal ranibizumab (Lucentis, 0.5 mg) treatment. One month after first injection, best-corrected visual acuity improved to 6/15 in her left eye. After six months, best-corrected visual acuity further improved to 6/12, with complete resolution subretinal fluid on ocular coherence tomography.
Key words:
age related macular degeneration, occult choroidal neovascularization, anti-VEGF, ranibizumab
Zdroje
1. Bressler NM, Bressler SB, Fine SL.: Age-related macular degeneration.Surv Opthalmol 1988; 32: 375–413.
2. Bressler NM.: Age-related macular degeneration is the leading cause of blindness. JAMA 2004; 291: 1900–1901.
3. Brown DM, Kaiser PK, Michels M. et al.: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432–1444.
4. Hee MR, Baumal CR, Puliafito CA. et al.: Optical coherence tomography of age-related macular degeneration and choriodal neovascularization. Opthalmogy1996; 103:1260–1270.
5. Margherio RR, Margherio AR, DeSantis ME.: Laser treatments with verteporfirin therapy and its potential impact on retinal practices. Retina 2000; 20: 325–330.
6. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N.: Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 623–632
Štítky
OphthalmologyČlánok vyšiel v časopise
Czech and Slovak Ophthalmology
2010 Číslo 3
Najčítanejšie v tomto čísle
- Treatment of the Choroidal Neovascular Membrane by Ranibizumab (Lucentis): A Case Report
- Epidemiology of the Age-Related Macular Degeneration
- The Change of the anti-VEGF Agent in the Treatment of Exceptionally Active Choroidal Neovascular Membrane in Age-Related Macular Degeneration
- Combined Therapy in the Exsudative Age-Related Macular Degeneration (Photodynamic Therapy and Intravitreally-Applied Ranibizumab)